Keros to Start Rinvatercept DMD Trial in Q1 2026, Plans ALS Regulatory Talks
Keros Therapeutics plans a phase II DMD trial of rinvatercept in Q1 2026 and regulatory talks for ALS in H2 2026. Cash stands at $383 million with runway into H1 2028.
dystrophin
GeneAlso known as: dystrophin gene
Related News
BioMarin Q2 2026 Revenues Up 20% to $990M; VOXZOGO Hypochondroplasia sNDA Filed
BioMarin reported Q2 2026 revenues of $990 million, up 20% Y/Y, and raised guidance. It filed an sNDA for VOXZOGO in hypochondroplasia and advanced BMN 333, BMN 820, and BMN 351.
EV-Based Gene Therapy Delivers Full-Length Dystrophin mRNA, Restores Muscle in DMD Models
Researchers at MD Anderson developed an extracellular vesicle-based platform that delivers full-length DMD mRNA, restoring dystrophin production and improving muscle function in preclinical Duchenne muscular dystrophy models. The study, published in Nature Biomedical Engineering, showed reduced side effects compared with viral gene therapies.
Deramiocel Slows Upper Limb Decline in Duchenne Muscular Dystrophy; FDA Review Ongoing
Phase III data show deramiocel slowed upper limb decline by 54% in Duchenne muscular dystrophy. The FDA is re-evaluating the BLA with HOPE-3 results, with a submission of the clinical study report expected in February 2026.
FDA Grants Rare Pediatric Disease Designation to Atossa's (Z)-Endoxifen for Duchenne Muscular Dystrophy
The FDA granted Rare Pediatric Disease designation to Atossa Therapeutics' (Z)-endoxifen for treating Duchenne Muscular Dystrophy. The designation may qualify the drug for a valuable Priority Review Voucher upon approval. Atossa reported a net loss of $34.8 million for 2025 as it advances clinical development.
Servier to Acquire Edgewise Muscular Dystrophy Unit for Up to $2.65 Billion
Servier will acquire Edgewise Therapeutics' muscular dystrophy business, including the drug sevasemten, for up to $2.65 billion. Sevasemten recently faced an FDA rejection for accelerated approval in Becker muscular dystrophy but is advancing to a Phase 3 trial in 2026. The drug has received multiple FDA and EMA designations for both Becker and Duchenne muscular dystrophy.
Solid Biosciences Advances SGT-003 DMD Gene Therapy with FDA Alignment, Reports No Liver Toxicity
Solid Biosciences has secured FDA alignment on a registration pathway for its Duchenne muscular dystrophy gene therapy SGT-003, with 36 patients dosed to date showing no drug-induced liver injury, myocarditis, or other serious adverse events reported with competing therapies.
FDA Grants Fast Track Designation to Precision BioSciences' DMD Gene Therapy
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy designed to treat patients with mutations in exons 45-55.
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD Gene Editing Therapy
Precision BioSciences announced FDA Fast Track designation for PBGENE-DMD, a first-in-class gene editing therapy for Duchenne muscular dystrophy targeting mutations in exons 45-55, representing up to 60% of DMD patients.
Chugai Launches ELEVIDYS as Japan's First Gene Therapy for Duchenne Muscular Dystrophy
Chugai Pharmaceutical launched ELEVIDYS in Japan as the first regenerative medical product for Duchenne muscular dystrophy following its listing on the National Health Insurance reimbursement price list on February 20, 2026.